Key result
Adjuvant chemotherapy, particularly with alkylating agents and anthracyclines, along with radiotherapy and G-CSF support, increases the risk of secondary acute myeloid leukemia in breast cancer survivors.
Why the study?
Does adjuvant therapy (chemotherapy, radiotherapy, G-CSF) increase the risk of therapy-related myeloid neoplasms in breast cancer survivors?
Does adjuvant therapy (chemotherapy, radiotherapy, G-CSF) increase the risk of therapy-related myeloid neoplasms in breast cancer survivors?
Adjuvant chemotherapy (especially alkylating agents and anthracyclines) and radiotherapy for breast cancer are associated with a small but significant increased risk of therapy-related myeloid neoplasms, which may be further enhanced by G-CSF support.
Answers are grounded in this paper and cite their sources.
Supports vigilant long-term AML surveillance in breast cancer survivors; leaves open precise risk stratification by regimen.
Breast cancer is the most frequent cancer among women and the leading cause of death among middle-aged women. Early detection by mammography screening and improvement of therapeutic options have increased breast cancer survival rates, with the consequence that late side effects of cancer treatment become increasingly important. In particular, patients treated with adjuvant chemotherapy regimens, commonly including alkylating agents and anthracyclines, are at increased risk of developing leukemia, further enhanced by the use of radiotherapy. In the last few years also the use of growth factors seems to increase the risk of secondary leukemia. The purpose of this review is to update epidemiology of therapy-related myeloid neoplasms occurring in breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Valentini et al. (2011) conducted a review in Breast cancer. Adjuvant chemotherapy, radiotherapy, and G-CSF was evaluated on Incidence of therapy-related myeloid neoplasms (t-MN) including acute myeloid leukemia and myelodysplastic syndromes. Adjuvant chemotherapy, particularly with alkylating agents and anthracyclines, along with radiotherapy and G-CSF support, increases the risk of secondary acute myeloid leukemia in breast cancer survivors.
Synapse has enriched 10 related papers. Consider them for comparative context: